74 results about "Host cell line" patented technology

The invention provides isolated polynucleotide molecules, including plasmids; viral vectors; and transfected host cells that comprise a DNA sequence encoding an infectious RNA sequence encoding a North American PRRS virus; and also North American PRRS viruses encoded thereby. The invention further provides isolated infectious RNA molecules encoding a North American PRRS virus. The invention also provides isolated polynucleotide molecules, infectious RNA molecules, viral vectors, and transfected host cells encoding genetically-modified North American PRRS viruses; and genetically-modified North American PRRS viruses encoded thereby. The invention also provides vaccines comprising such plasmids, RNA molecules, viral vectors, and North American PRRS viruses, and methods of using these vaccines in swine and in other animals. Also provided are isolated polynucleotide molecules, viral vectors, and transfected host cells that comprise a nucleotide sequence encoding a peptide of a North American PRRS virus. These viral vectors and transfected host cell lines are useful in providing peptides to compensate for mutated peptide coding sequences of DNA sequences encoding genetically-modified North American PRRS viruses so that functional virions can be generated.

The present invention relates to recombinant bovine parainfluenza virus (bPIV) cDNA or RNA which may be used to express heterologous gene products in appropriate host cell systems and/or to rescue negative strand RNA recombinant viruses that express, package, and/or present the heterologous gene product. In particular, the heterologous gene products include gene product of another species of PIV or from another negative strand RNA virus, including but not limited to, influenza virus, respiratory syncytial virus, human metapneumovirus and avian pneumovirus. The chimeric viruses and expression products may advantageously be used in vaccine formulations including vaccines against a broad range of pathogens and antigens.

The invention discloses a method and application for screening an ultralow fucose cell line. The invention provides a method for constructing fucose deficit type host cells capable of expressing an antibody and an IgG-FC fusion protein, a detection method for the fucose activity of the antibody and the IgG-Fc fusion protein, and concrete application of the cell lines. The method provided by the invention is realized by highly-efficient knockout of fucose-based transferase (FUT8) gene in an engineering cell producing the antibodies and the IgG-Fc fusion protein through a TALEN (and/or CRISPR) technology; and through lens culinaris lectin (LCA) pressurizing, gene sequencing and a flow cytometry screening process, the host cells with highly-efficiently knocked-out fucose is obtained. Meanwhile, fucose deficit CHOK1 host cell lines are constructed into stable engineering cell lines capable of expressing antibody proteins; and after the antibody proteins are obtained, glycoform analysis is performed; and results show that fucose knockout efficiency reaches to 99% or above.

The present invention provides recombinant nucleic acid molecules encoding a chimeric transactivator protein including a DNA binding domain of a DNA binding protein and a protein domain capable of transcriptional activation. The present invention also provides recombinant viral and non-viral vectors that are able to infect and/or transfect and sustain expression of a biologically active chimeric transactivator proteins in mammalian cells. Also provided are host cell lines and non-human transgenic animals capable of expressing biologically active chimeric transactivator proteins. In another aspect, compositions and methods for treating or preventing ischemic damage associated with hypoxia-related disorders are provided.

The invention provides a method for preparing triple vaccine for preventing porcine transmissible gastroenteritis, porcine epidemic diarrhea and porcine rotavirus. The method comprises the following steps: inoculating a host-cell line with a 90 percent grown monostratum against a porcine transmissible gastroenteritis virus, a porcine epidemic diarrhea virus and a porcine rotavirus respectively, and adding a cell maintenance media into the host-cell lines respectively to be cultured at 37 DEG C; after cytopathic effect reaches over 75 percent, collecting viruses to be stored at 20 DEG C below zero for standby; mixing the viruses according to 10 TCID50 in 1:1:1, and simultaneously adding Freund's complete adjuvant and immunopotentiator into the mixture to inactivate the mixture by formaldehyde at 37 DEG C for 24 hours; and adding an oil adjuvant into the mixture to prepare a vaccine of water-oil-water preparation. The method can be used for preparing the triple vaccine for preventing the porcine transmissible gastroenteritis, the porcine epidemic diarrhea and the porcine rotavirus so as to solve the problem that the diseases do not have an effective medicine to treat currently.

Described herein are antibodies that bind to human tumor necrosis factor alpha (hTNFα). And list the nucleotide sequence of antibody heavy chain and light chain variable region and its derived amino acid sequence. The heavy chain and light chain variable region genes are respectively connected with the human immunoglobulin gamma 1 (hIgG1) heavy chain constant region and human kappa (k) light chain constant region genes to form a chimeric gene. Then, the vector containing the chimeric gene is introduced into the host cell line to express the antibody protein. This recombinant chimeric antibody protein can neutralize the activity of hTNFα in vitro, and is suitable for treating patients with excessive secretion of harmful hTNFα, including certain inflammations, such as rheumatoid arthritis and Crohn's disease.

The invention belongs to the field of gene therapy, and particularly relates to a preparation method and system of recombinant adeno-associated virus and recombinant bacmids. Firstly, constructing recombinant bacmids of a recombinant baculovirus genome containing necessary functional elements for producing the recombinant adeno-associated virus; wherein at least one necessary functional element isinserted into the N terminal or the C terminal of the necessary locus of the recombinant baculovirus genome; and then transfecting the obtained recombinant bacmids containing the recombinant baculovirus genome for producing the recombinant adeno-associated virus into a host cell line for culturing to prepare the recombinant adeno-associated virus. Compared with a recombinant baculovirus obtainedby preparing recombinant bacmids through traditional Tn7 recombination, the recombinant baculovirus obtained by inserting core elements containing Cap, Rep and ITR into the two sides of an essential gene of the baculovirus has the advantages that the production level of continuous passage rAAV in cells is more stable, and the rAAV yield is higher.

A method for selecting host cells with an improved ability to recombinantly overexpress a target protein; the host cells thus generated and their use. The invention also provides a curing method to remove plasmids from host cell lines.

The present invention relates to recombinant bovine parainfluenza virus (bPIV) cDNA or RNA which may be used to express heterologous gene products in appropriate host cell systems and/or to rescue negative strand RNA recombinant viruses that express, package, and/or present the heterologous gene product. The chimeric viruses and expression products may advantageously be used in vaccine formulations including vaccines against a broad range of pathogens and antigens.

The invention discloses a preparation method and system of recombinant adeno-associated virus (rAAV), and recombinant bacmid. The method comprises: (1) separately preparing shuttle plasmids and a corresponding recombinant bacmid containing baculovirus genome; (2) integrating a rAAV core expression element which has a heterologous functional gene fragment with other expression cassettes which produce functional protein components necessary for rAAV so as to obtain a recombinant bacmid containing recombinant baculovirus genome producing the rAAV; and (3) transfecting the obtained recombinant bacmid into a host cell line for culturing. The system comprises the shuttle plasmids and the corresponding recombinant bacmid containing the baculovirus genome. The recombinant bacmid comprises at leastone expression cassette that produces functional protein components necessary for rAAV. The system has flexibility, compatibility, and higher passage stability.

The invention concerns the field of cell culture technology. It concerns production host cell lines with increased expression of ribosomal RNA (rRNA) achieved through reducing expression of NoCR proteins, especially of TIP-5. Those cell lines have improved secretion and growth characteristics in comparison to control cell lines. The invention further concerns a method of producing proteins using the cells generated by the described method.

Host cell lines for biopharmaceutical production of antibodies, antibody fragments or antibody-derived fusion proteins are selected as having the capability of inducing improved cellular effector functions, e.g., Fc-medicated effector functions. The host cells are derived from the rat myeloma cell line YB2/0 and are adapted to growth in chemically-defined medium.

The invention relates to a cross-barrier targeted drug delivery system for lesions, a drug-carrier system and a host cell system. The drug delivery system comprises cross-barrier virus-like particlesand lesion-targeting virus-like particles, wherein the cross-barrier virus-like particles carry cross-barrier signals, and the lesion-targeting virus-like particles carry lesion-targeting signals. Thecross-barrier virus-like particles and the lesion-targeting virus-like particles are capable of performing self-assembly to form heteropoly virus-like particles. The drug delivery system has the dualfunctions of cross-barrier and targeted transportation to the lesions, and meanwhile, the virus-like particles have the advantages of safety and high transportation efficiency.

Described herein are antibodies and mixtures of antibodies optionally produced by a host cell line, nucleic acids encoding the antibodies and mixtures of antibodies, host cells containing such nucleicacids, and methods of treatment using the antibodies, mixtures of antibodies, or nucleic acids encoding the antibodies or mixtures of antibodies. Also described are methods of producing mixtures of antibodies in host cells.

The present invention concerns the field of cell culture technology. It describes a novel method for enhancing the secretory transport of proteins in eukaryotic cells by heterologous expression of Munc18c, Sly1 or other members of the SM protein family. This method is particularly useful for the generation of optimized host cell systems with enhanced production capacity for the expression and manufacture of recombinant protein products.

The invention relates to a medium being able to optimize virus replication. The medium contains a fusion protein E with the concentration of 100-1000nM, and a cell line is a host cell line over-expressing the fusion protein E gene. The fusion protein E can improve the TCID50 tilter of various viruses by 1-3 lg units and improve the HA tilter by 2-4 lg2 units, the various viruses comprise coronavirus, paramyxovirus, orthomyxovirus, reovirus and herpes virus, the fusion protein E has no cytotoxicity in a prescribed dosage, breaks a boundary between DNA viruses and RNA viruses, and also breaks the boundary between viruses with envelopes and viruses without envelopes. The fusion protein E obtained through a prokaryotic expression system has a high expression efficiency, and can be easily purified, the one-step purification efficiency can reach 85% or above, and the final concentration of the protein can reach 3mg/ml. The fusion protein E can be directly added to the virus medium in order to improve the tilter of various virus vaccines, so the medium is simple and fast. The medium has great influences and meanings in the production, learning and research of the virus subject.

The present invention discloses compositions and methods for high-level, large-scale production of recombinant proteins. Exemplary combinations comprise one or more expression vectors capable of high-level expression of recombinant proteins and/or polypeptides, and immortalized host cell lines capable of growth in serum-free, suspension culture conditions. Bi-directional UCOE vectors allow simultaneous high-level expression of two or more recombinant proteins and/or polypeptides on a single UCOE-based plasmid vector.